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Abstract
Background: The role of exogenous hormone exposures in the development of meningioma is
unclear, but these exposures have been proposed as one hypothesis to explain the over-abundance
of such tumors in women.
Methods: The association between oral contraception (OC) or hormone replacement therapy
(HRT) and intracranial meningioma in women was investigated using a population-based, matched
case-control study. Exposures for 143 cases and 286 controls matched on age within five years
were obtained by interview. Diagnoses were confirmed histopathologically and estrogen and
progesterone receptor assays conducted.
Results: Although risk of meningioma appeared modestly elevated in past OC users (OR = 1.5,
95% CI 0.8 – 2.7), and in current users (OR = 2.5, 95% CI 0.5 – 12.6), the confidence intervals were
wide. No significant association between meningioma risk and duration of OC use was found.
Likewise, risk of meningioma was only weakly associated with past use of HRT (OR = 0.7, 95% CI
0.4 – 1.3), and not at all with current use of HRT (OR = 1.0, 95% CI 0.5 – 2.2). Of 142 available
specimens, 2 (1%) expressed estrogen receptors, whereas 130 (92%) expressed progesterone
receptors (PR). OC use was associated with increased risk of a meningioma expressing less rather
than more PR (OR = 3.2, 95% CI 1.3 – 8.0). Overall, in post menopausal women, HRT use appeared
to confer a non-significant protective effect, and was not associated with low or high PR expressing
meningiomas.
Conclusion: This study found little evidence of associations between meningioma and exogenous
hormone exposures in women but did suggest that some hormonal exposures may influence tumor
biology in those women who develop meningioma.
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Background
Meningiomas occur more frequently in women than men
and have the highest incidence in the fifth and sixth dec-
ades of life[1,2]. Consistent with data from other studies
in North America and Europe, we have previously
reported the incidence of intracranial meningioma in
western Washington State to be 3.2 per 100,000 person-
years, with women comprising 69% of the meningioma
diagnoses and the highest age- and gender-specific inci-
dence of over 7 per 100,000 person-years in women 60
years or older[3].
Research has focused on the similarities and risk factors
common to meningioma and other neoplasms in addi-
tion to other mechanisms. In particular, meningioma may
be associated with breast carcinoma[4,5] but this associa-
tion may not be a direct link and instead may rely on the
common predispositions of gender, age, and reproductive
factors. Hormonal exposures have a suspected role in the
etiology of both neoplasms[6]. The Women's Health Ini-
tiative (WHI) study, a large randomized trial, found an
increased risk for breast carcinoma in post-menopausal
women using opposed hormone replacement therapy
(estrogen and progestin)[7]. In a separate WHI analysis,
results of unopposed estrogen exposure suggest a non-sig-
nificant reduction in the risk of breast carcinoma[8].
Observational studies examining hormone replacement
therapy and breast carcinoma have reported results gener-
ally in agreement with the randomized trials [9-11]. Evi-
dence for an association between oral contraception and
breast carcinoma remains equivocal[9,12-16]. A recent
report from a case-control study found few significant
associations between reproductive or hormonal factors
and the risk of meningioma[17]. However, results from
the Nurses' Health Study cohort, suggest the risk of men-
ingioma is increased among women exposed to either
endogenous or exogenous sex hormones[18]. As part of a
case-control study designed to investigate putative risk
factors for intracranial meningioma, we evaluated the
association between intracranial meningioma and sex
hormone exposures, and in relation to hormone receptor
expression in the tumors.
Methods
We conducted a population-based, matched case-control
study of risk factors for intracranial meningioma, as
detailed previously[3,19]. Institutional Review Boards at
the University of Washington and the Fred Hutchinson
Cancer Research Center approved the study. All inter-
viewed subjects provided signed, informed consent before
study participation. We identified cases with incident
intracranial meningioma, histologically confirmed during
life between January 1, 1995 and June 30, 1998, using the
National Cancer Institute's Surveillance, Epidemiology,
and End Results program for King, Pierce and Snohomish
counties of western Washington State, which together had
a population of nearly 2.8 million at the mid-point of the
study. Using random-digit dialing or Medicare eligibility
lists, we recruited two controls for each case matched on
gender, age within 5 years, and county of residence. The
participation proportion for each method of control
recruitment was calculated as a percentage based on the
number of participants divided by the number of subjects
screened and found eligible using that recruitment
method. All cases and controls were 18 years or older.
Exposure histories were obtained from all enrolled partic-
ipants through a structured in-person interview and ques-
tionnaire that focused on the entire history of exposures
before the reference date. Reference date was the date of
the case's surgery that yielded histological confirmation
and was the same for the case's matched controls. Seven
of the 143 female cases identified for this study were una-
ble to complete the interview due to disability or death.
Proxy interviews of a spouse or next-of-kin were con-
ducted for these cases, but were not conducted for the
matched controls. For reproductive and medical history in
women, we specifically asked about factors such as age at
menarche, pregnancy, breastfeeding, and menstrual status
in addition to other exposures common to both men and
women. For use of oral contraceptives and hormone
replacement therapy, we inquired about the type of pre-
scription using visual prompts, the calendar time of use,
and duration of use for any hormone therapy. Interview
responses on the type of oral contraceptive preparation
used were often incomplete, and so we were unable to
examine the influence of the type of preparation on the
risk of meningioma.
For all 143 cases, we confirmed the meningioma diagno-
sis by requesting tumor specimens and pathology reports
from the resecting hospital. The study neuropathologist
confirmed the diagnosis of meningioma. In addition,
specimens were submitted to Phenopath Laboratories,
Seattle, Washington, for estrogen and progesterone recep-
tor analysis. New tumor tissue slices were prepared from
specimens embedded in paraffin, pretreated in citrate
buffer pH 6.0 in a steamer for 30 minutes, and placed on
an autostainer. For estrogen receptor analysis, antibody
clone 1D4 was used (Dako Corporation, Carpentaria, CA,
USA). For progesterone receptor analysis, antibody clone
88 was used (BioGenex, San Ramon, CA, USA). Detection
was performed using the labeled streptavidin-biotin sys-
tem (LSAB+) with horseradish peroxidase followed by
3,3'-diaminobenzidine chromogen (DAB+). Receptor
assays were successful in all but one case.
Analysis
We used conditional logistic regression to measure the
association between each exposure and intracranial men-BMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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ingioma. For all analyses, we used never-exposed or no
exposure as the referent category. Results are reported as
odds ratios (OR) with 95% confidence intervals (CI).
Where appropriate, tests for linear trend were conducted.
Multiplicative interactions were assessed using the likeli-
hood ratio (LR) test. Given their slow growth, most men-
ingiomas have probably been present for a decade or
more by the time a diagnosis is made[20]. Therefore each
analysis was repeated for exposures beginning at least 10
years before the reference date. We also compared the con-
ditional logistic regression results to unconditional results
of models with the same variables. Because the results for
these comparisons were not substantially different we
elected to report the results using conditional logistic
regression as it was the originally proposed methodology
for the study. In exploratory analyses, we used polyto-
mous logistic regression to compare hormone exposure
categories for controls to cases with tumors that had abun-
dant hormone receptor expression and to cases with
tumors that had little or no hormone receptor expression.
The odds ratios for these analyses measure the association
between exposure and case-control status, examined sep-
arately according to the two case groups defined by recep-
tor status rather than between exposure and receptor
status among cases only. For both conditional logistic
regression and the exploratory polytomous regression, we
assessed whether other variables were potential con-
founders, such as age, education, smoking history, alco-
hol consumption, body mass index, age at menarche, and
parity. When necessary in stratified analyses, we used
unconditional logistic regression in order to prevent the
loss of data for case-control groups that were concordant
on the specific exposures of interest. Analyses were con-
ducted using Stata (version 9, Stata Corporation, College
Station, TX, USA).
Results
Although the 143 cases and 286 matched controls were
similar on age, race and marital status, controls were more
educated than cases (Table 1). Because education was a
confounder, we included it in all multivariable models as
a categorical variable: high school or less, some college or
trade school, college graduate. Also, because on average
cases were 0.9 years older than the first matched control
and 1.6 years older than the second matched control, we
included age in all multivariable models as a continuous
variable to address residual confounding. Case participa-
tion was 84%. For controls identified through random
digit dialing 55% participated, and for controls identified
using Medicare eligibility 67% participated. On average
cases were interviewed 410 days after the reference date
and controls were interviewed 839 days after the reference
date.
Oral contraception
With never-users of oral contraceptives as the referent
group, the odds ratios for past users or current users on the
reference date were both greater than 1.0 but not signifi-
cantly so (Table 2). A graded effect (linear trend) with
years of use or initiation of use relative to the reference
Table 1: Demographic characteristics of women with intracranial meningioma and age and gender-matched controls
Demographic Characteristic Cases N = 143 Number (Percent) Controls N = 286 Number (Percent)
Age Group
< 40 21 (15) 51 (18)
40–49 39 (27) 77 (27)
50–59 32 (22) 58 (20)
60–69 23 (16) 50 (18)
≥ 70 28 (20) 50 (18)
Race
Caucasian 129 (90) 266 (93)
African American 2 (1) 7 (3)
Native American 3 (2) 4 (1)
Hispanic 2 (1) 4 (1)
Asian American 1 (1) 3 (1)
Other 6 (4) 2 (1)
Marital Status
Single 15 (10) 34 (12)
Married 90 (62) 189 (66)
Separated/Divorced 16 (11) 33 (12)
Widowed 22 (15) 30 (11)
Educational Attainment
Grade school 1 (1) 7 (3)
High school 54 (38) 72 (25)
Some college 74 (52) 165 (58)
Graduate school 14 (10) 42 (15)BMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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date was not apparent. Tests for interaction did not reveal
significant interactions between oral contraceptive use
and pregnancy, number of pregnancies, number of live
births, body mass index, hormone replacement therapy,
or breastfeeding.
Hormone replacement therapy
Analysis of the association between hormone replace-
ment therapy and meningioma was restricted to postmen-
opausal women. Two hundred and seventy three women
(101 cases, 172 controls) reported they were no longer
menstruating on the corresponding reference date for
each matched group. Of these women, 63 (62%) cases
and 114 (66%) controls reported hormone replacement
therapy use on or before the reference date.
We found no statistically significant association between
hormone replacement therapy and meningioma. With
never users of hormone replacement therapy as the refer-
ent group, the odds ratio for women reporting past use
was lower than 1.0 but not significantly so (Table 3). Cur-
rent use on the reference date was not associated with
meningioma. A trend with increased years of use or initi-
ation of use relative to the reference date was not appar-
ent. Odds ratios for the type of hormone replacement
therapy did not indicate a significantly increased risk of
meningioma for either opposed or unopposed estrogen.
Table 2: Association between oral contraceptive use and intracranial meningioma in women
Exposure* Cases n Controls n OR (95% CI)†
Oral contraception (O C)
Never 48 103 Referent
Past 90 176 1.5 (0.8 – 2.7)
Current use on reference date 5 7 2.5 (0.5 – 12.6)
Years of OC use
Never 48 103 Referent
Up to 5 years 49 90 1.5 (0.8 – 3.0)
More than 5 years 46 93 1.4 (0.7 – 2.7)
First OC exposure relative to reference date
Never 48 103 Referent
1–9 years before 7 15 1.6 (0.3 – 7.5)
10 or more years before 88 168 1.5 (0.8 – 2.7)
* Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma.
† Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three 
categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None 
of the tests for linear trend was significant.
Table 3: Association between hormone replace therapy and intracranial meningioma in post-menopausal women
Exposure* Cases n Controls n OR (95% CI)†
Hormone replacement therapy (HRT)
Never 38 58 Referent
Past 40 73 0.7 (0.4 – 1.3)
Current use on reference date 23 41 1.0 (0.4 – 2.2)
Years of HRT use
Never 38 58 Referent
Up to 5 years 28 43 0.9 (0.4 – 1.7)
More than 5 years 32 65 0.9 (0.5 – 1.7)
First HRT exposure relative to reference date
Never 38 58 Referent
1–9 years before 30 44 0.9 (0.4 – 1.9)
10 or more years before 31 62 0.9 (0.5 – 1.6)
Type of HRT preparation
None 38 58 Referent
Estrogen 33 66 0.9 (0.5 – 1.6)
Estrogen and Progestin 24 33 1.3 (0.6 – 2.8)
* Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma.
† Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three 
categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None 
of the tests for linear trend was significant.BMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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Tests for interaction did not reveal significant interactions
between hormone replacement therapy and smoking, pre-
vious pregnancy, number of pregnancies, number of live
births, breastfeeding, oral contraceptive use, or body mass
index.
We examined a potential combined effect of hormone
replacement therapy and past oral contraceptive use in
post menopausal women compared to never exposed
women by grouping women into three categories: expo-
sure to both, exposure to one or the other and never expo-
sure, and we also examined duration of exposure as never,
up to ten years, and ten or more years. In each analysis,
point estimates and associated confidence intervals were
not appreciably different than for hormone replacement
therapy alone (results not shown).
Results for either oral contraception or hormone replace-
ment therapy were unchanged when the seven cases in
whom proxies interviews were used and their matched
controls were removed from the analyses (results not
shown).
Reproductive and related exposure categories
We evaluated several exposure categories related to repro-
duction and endogenous hormones, including age at
menarche, number of live births, age at first live birth, his-
tory of breastfeeding and did not find significant associa-
tions with meningioma (Table 4). In addition we
evaluated if reporting menstrual cycles or being post-men-
opausal on the reference date and also 10 years before the
reference date were related to the risk of meningioma. In
these analyses we used unconditional logistic regression,
restricted to post-menopausal women who did not use
HRT. The odds ratio for the risk of meningioma in women
who were post-menopausal on the reference date was 3.1
(95% CI, 1.2 – 7.9) compared to women who were men-
struating and was 0.6 (95%, CI, 0.2 – 1.9) in women who
were post-menopausal ten years before the reference date
even after adjusting for age and education.
We also assessed body mass index (BMI) grouped as
under/normal weight (<25), overweight (25–30), and
obese (≥30)[21]. Compared to under/normal weight
women on the reference date, the risk of meningioma in
overweight women was 1.2 (95% CI, 0.7 – 2.0) and was
1.5 (95% CI, 0.9 – 2.4) in obese women.
Table 4: Reproductive history and related endogenous exposures
Exposure* Cases n Controls n OR (95% CI)†
Age at menarche
< 12 22 44 Referent
12 – 14 100 212 0.9 (0.5 – 1.7)
> 14 21 30 1.2 (0.6 – 2.7)
Number of live births
None 18 58 Referent
1 22 28 2.0 (0.9 – 4.6)
≥ 2 103 200 1.4 (0.7 – 2.6)
Age at first birth
< 20 25 44 Referent
20 – 29 86 159 1.2 (0.6 – 2.4)
≥ 30 14 25 1.2 (0.4 – 3.8)
Ever Breast Feeding
No 57 75 Referent
Yes 71 154 0.7 (0.4 – 1.0)
Menstrual status on reference date**
Menstruating 21 72 Referent
Post-menopausal and not using
HRT
38 58 2.8 (1.1 – 7.1)
Menstrual status 10 years before reference date**
Menstruating 35 83 Referent
Post-menopausal and not using
HRT
23 46 0.6 (0.2 – 1.9)
* Reported exposure before reference date, which for a case and her two matched controls was the date the case had surgery for her meningioma.
† Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable conditional logistic regression including continuous age and three 
categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. None 
of the tests for linear trend was significant.
** Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable unconditional logistic regression including continuous age and 
three categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables.BMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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Hormone receptor expression
Progesterone receptor (PR) expression was common with
62 (44%) of tumors having >75% of cells expressing PR,
35 (24%) of tumors having 25–75 percent of cells express-
ing PR, 33 (23%) of tumors having <25% of cells express-
ing PR, and 12 (8%) of tumors with no cells expressing
PR. In contrast, estrogen receptor (ER) expression was
uncommon with only 1 tumor having >75% cells express-
ing ER and 1 tumor with <25% of cells expressing ER. The
remaining 140 tumors (98%) did not express ER. In
exploratory analyses we focused on associations between
exposure categories and progesterone receptor expression
dichotomized as low (<25% of cells expressing PR) or
high (25% or more expressing PR). We were unable to
compare never, current and past oral contraceptives or
hormone replacement therapy use to PR expression due to
insufficient numbers, so we compared never and ever oral
contraceptive or hormone replacement therapy exposure
(Table 5). We found a strong association between oral
contraceptive use and risk of a tumor expressing low, but
not high, PR compared to controls. We also found a posi-
tive association between number of live births and risk of
a tumor expressing low, but not high, PR compared to
controls. For post-menopausal women, we did not
observe evidence of an association between hormone
replacement therapy and a tumor expressing low or high
PR. While we found evidence for an association between
meningioma and menstruating 10 years before the refer-
ence date, we did not find a difference in risk for cases
whose tumors expressed low or high PR.
Discussion
We used a population-based case-control study of risk fac-
tors for intracranial meningioma to assess hormonal
Table 5: Association between exposure categories and progesterone receptor expression
Explanatory 
Variable
Controls Cases with tumors expressing PR* in 0 to 
25% of cells
Cases with tumors expressing PR* in = 
order 25 to 100% of cells
n n OR (95% CI)† nO R  ( 9 5 %  C I ) †
OC* use
Never 103 15 Referent 33 Referent
Ever 183 31 3.2 (1.3 – 8.0) 64 1.1 (0.6 – 1.9)
HRT* use in post-menopausal women
Never 58 15 Referent 23 Referent
Ever 114 22 0.8 (0.4 – 1.6) 41 0.9 (0.5 – 1.6)
Current menstrual status
Menstruating 114 9 Referent 33 Referent
Post-menopausal 172 37 2.7 (1.2 – 5.8) 64 1.3 (0.8 – 2.1)
Menstrual status 10 years before reference date
Menstruating 158 21 Referent 62 Referent
Post-menopausal 126 23 0.5 (0.2 – 1.5) 35 0.5 (0.2 – 1.0)
Current menstrual status
Menstruating 72 4 Referent 17 Referent
Post-menopausal and
not using HRT
58 15 2.4 (1.2 – 5.8) 23 3.1 (1.1 – 8.6)
Menstrual status 10 years before reference date
Menstruating 83 8 Referent 27 Referent
Post-menopausal and
not using HRT
46 10 0.3 (0.1 – 2.5) 13 0.8 (0.5 – 1.3)
Smoking status 10 years before reference date
Non-smoker 144 29 Referent 48 Referent
Smoker 142 17 0.5 (0.3 – 1.0) 49 1.0 (0.6 – 1.5)
Body Mass Index on reference date
< 25 156 23 Referent 45 Referent
25 – 30 66 12 1.2 (0.5 – 2.5) 22 1.1 (0.5 – 2.4)
≥ 30 64 11 1.1 (0.6 – 2.0) 29 1.5 (0.8 – 2.6)
Number of live births
None 58 2 Referent 16 Referent
1 28 5 4.0 (0.7 – 22.3) 17 2.1 (0.9 – 4.9)
≥ 2 200 39 4.3 (1.0 – 18.8) 64 1.1 (0.6 – 2.2)
*PR, progesterone receptor; OC, oral contraceptive; HRT, hormone replacement therapy
† Odds ratio (OR) and 95% confidence intervals (CI) estimated from multivariable polytomous logistic regression including continuous age and 
three categories of education (high school or less, some college or trade school, and college graduate or graduate school) as confounding variables. 
None of the tests for linear trend was significant.BMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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exposures and the risk of subsequent meningioma in
women. Overall, the associations between meningioma
and oral contraceptives or hormone replacement therapy
in this study were relatively weak. The direction of associ-
ation was toward higher risk of meningioma among past
or current oral contraceptive users, and among users of
combined estrogen-progestin hormone supplements in
menopause, while the direction was toward lower risk
among women who used unopposed estrogen during
menopause. However, confidence intervals around these
odds ratios were wide and included one. While current
post-menopausal status was associated with an increased
risk of meningioma, post-menopausal status 10 years
before the reference date had a non-significant protective
effect. Exposures in this time frame are consistent with the
theory of meningioma development where symptoms
and diagnosis often occur 10 or more years after the initial
establishment of the tumor[19].
The finding that meningioma risk is increased among
women who were postmenopausal on the reference date,
but decreased among women who were postmenopausal
10 years prior to the reference date is curious and could be
due to chance given the number of comparisons made.
However, a potential explanation is that the risk of devel-
oping meningioma may be associated with changing hor-
monal levels as opposed to the presence or absence of
female sex hormones. The interval of transition from pre-
menopausal hormone production to reduced production
of endogenous hormones may be a risk factor for menin-
gioma growth. Women who do not develop an apparent
meningioma at this time pass through this higher risk
window and enter a lower risk window.
The frequency with which meningioma tumors express
estrogen receptors remains unclear with researchers
reporting between 0 to 94% prevalence[6]. In this study
only 2 of 142 specimens expressed estrogen receptors for
a prevalence of 1.4%, whereas 130 tumors (92%)
expressed progesterone receptors. The presence of proges-
terone receptor expression in meningioma tissue has been
observed in previous pathology studies[14,16,22]. We
were able to consider the combination of progesterone
receptor expression and hormone exposure history. Oth-
ers have observed that the grade of meningioma and like-
lihood of recurrence are related to progesterone receptor
expression with tumors lacking such expression more
likely to be higher grade and to recur[16,23] Results for
history of live births were similar to those observed for
oral contraceptives, with these exposures significantly or
near significantly associated with tumors that have little
or no PR expression. Hormone use could accelerate, retard
or have no effect on growth of a meningioma. Whether
growth is accelerated or retarded would depend on the
specific biochemical pathways that are activated by the
receptor when a hormone is present, whereas hormone
use might plausibly have no effect on growth in tumors
that do not express receptors. Though our study was not
designed to assess this question, these results could be
used to form a hypothesis for a study that seeks to deter-
mine whether progesterone receptor expression is related
to several exposure categories, and to determine whether
prognosis based on PR expression may differ based on
endogenous and exogenous hormone exposures.
Our results suggesting little evidence for associations
between reproductive and related exposure categories and
meningioma are similar to those recently reported by
Hatch and colleagues from a hospital-based case-control
study of women consisting of 151 meningioma cases and
436 frequency-matched controls[17]. In this study, the
point estimates of the odds ratios between meningioma
and current or past use of OC were somewhat higher than
those from the Nurses' Health Study cohort but the asso-
ciations were not statistically significant in either
study[18]. We did not find significant evidence of
increased risk of meningioma in women who are past and
current hormone replacement therapy users as reported
by Jhawar and colleagues. We believe our ascertainment
and pathological confirmation of meningioma for all
cases and structured interview including visual prompts to
ascertain hormone therapy exposure provide reliable data
on disease and exposure history. However, interpretation
of these results is difficult due to small numbers, unstable
estimates, and inconsistencies with prior works.
This study cannot rule out a modest association between
the risk of meningioma and body mass index as this find-
ing is similar in both our study and that of Jhawar and col-
leagues. However, both height and weight were self-
reported during the interview and may be subject to
reporting error[24]. Our body mass index categories are
consistent with those typically applied to the U.S. popula-
tion[21,25,26]. Although Jhawar and colleagues used BMI
categories consistent with the World Health Organization
categories, which have lower cut-off values for overweight
and obese groups, in both studies the same magnitude of
increasing risk of meningioma was observed with increas-
ing BMI.
This study has limitations. Chiefly, while disease status
was confirmed, all exposures are self-reported, and we did
not attempt to validate these exposures using medical or
pharmacy records. Point estimates for several exposure
categories suggest either elevated or reduced risk of men-
ingioma, but the available sample sizes were not sufficient
for specific combinations of exposures to suggest a coher-
ent pattern of association. Furthermore, due to incom-
plete responses for oral contraceptive preparations we
were unable to assess whether there is a different risk ofBMC Cancer 2006, 6:152 http://www.biomedcentral.com/1471-2407/6/152
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meningioma resulting from opposed versus unopposed
estrogen preparations. Analysis of all oral contraceptive
preparations together could obscure an association
between specific hormone preparations.
One potential limitation is related to the recruitment of
controls. Random digit dialing was used to identify con-
trols. In persons 65 years or older, random digit dialing
was observed to be inefficient, so Medicare eligibility lists
were used to identify controls. In each case our participa-
tion proportion was over 50% of the eligible controls.
These participation proportions are consistent with those
reported for other epidemiologic studies[27]. However,
we cannot rule out that selection bias could play a role in
our generally non-significant conditional logistic regres-
sion findings.
Another limitation is the potential for differential recall
based on the elapsed time from reference date to the inter-
view. However, we believe the potential for differential
recall is more apt to be related to the nature of the refer-
ence date as opposed to time between the reference date
and the interview date. For cases the reference date is the
date of surgical resection of the meningioma, whereas for
controls it is the date of surgery for the matched case,
which is unlikely to have inherent meaning for the con-
trols. To limit differential recall participants were asked to
focus on specific time periods of interest beginning with
exposure that would have been years before the reference
date. The trained interviewers used memory priming tech-
niques to facilitate recall of events before initiation of the
interviews. For sex hormone and reproductive history,
both current and remote exposure histories were assessed.
Although the presence of an association between menin-
gioma and breast carcinoma remains uncertain, evidence
of consistent findings for the role of specific exposures for
both categories of neoplasm is mounting. Reports suggest
the association between either oral contraceptive use or
postmenopausal hormone use and risk of breast carci-
noma may differ in relation to histopathology[28,29].
However, similar to reports for breast carcinoma, post-
menopausal women who used unopposed estrogen
(estrogen replacement therapy) had a either a reduced or
no observed increase in the risk of meningioma whereas
women who used opposed estrogen therapy had a modest
increased risk of meningioma[10,30].
Conclusion
The analyses of the association between meningioma and
female sex hormones suggests that certain exposures may
influence tumor biology and additional, larger studies
that specifically assess whether hormone exposures and
receptor expression are linked would help advance the
understanding of why some women develop these rela-
tively rare tumors while others do not. Overall the associ-
ation between oral contraceptives or hormone
replacement therapy and meningioma in women
reported here is consistent with other studies and is not
sufficiently evident to raise specific concerns about or sug-
gest changes to current hormone therapy guidelines.
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